{"name":"Elutia","slug":"elutia","ticker":"ELUT","exchange":"NASDAQ","domain":"elutia.com","description":"Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, ","hq":"Silver Spring, MD","founded":2017,"employees":"25","ceo":"Robert Rankin","sector":"Regenerative Medicine / Surgical Biologics","stockPrice":1.03,"stockChange":-0.02,"stockChangePercent":-1.9,"marketCap":"$48M","metrics":{"revenue":12293000,"revenueGrowth":16.2,"grossMargin":53.7,"rdSpend":4163000,"netIncome":53380000,"cash":36350000,"dividendYield":0,"peRatio":-0.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Tissue Repair Technology patent cliff ($100M at risk)","drug":"Tissue Repair Technology","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"Elutia Receives FDA Approval for Tissue Repair Technology","summary":"Elutia announced that it has received FDA approval for its proprietary tissue repair technology, marking a significant milestone for the company.","drugName":"Tissue Repair Technology","sentiment":"positive"},{"date":"2023-11-01","type":"earnings","headline":"Elutia Reports Strong Q3 Earnings","summary":"Elutia reported strong Q3 earnings, driven by growing revenue from its tissue repair technology.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQUmpFRzZJM0J0MFk4QWYwajVzdVB4eEM0VXNQaHpPY29jQlF5ZE5GRWhYbnFKS19OaFpUdFZPZ0lwUWJOZXVDY3JsNjgwQm1JRHlUbXNxVGRaZnBPcW13Z1daWjN4YlRyeHJoSmltblp3ZXJsM3NyNUJfSUdsUnp1MWczcHItMFZRbURHNXM1YlNyVF9heXQ3RzNpRW9IVUdDT0pRTWJQZEpyaF9mNmxhWmdwdW9hdi1seU94ZHJYcw?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"Elutia details tech to address infections in breast reconstruction - Stock Titan","headline":"Elutia details tech to address infections in breast reconstruction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNWjdJa096QkVDTVpCZmhFZlNyZ0tGdFkyTmJIQmZKelA1VFZlc3lVelFScWd1WTVYeVBlZHI1dUxZWi1kNEtJVzdYcEE5UXJ6amQtOU1iYWVmS0VqR2JFRjlYTGF0VFRjZTBIRHNWamYtODBNMUdpeGhmQVVVWU9HYzhXRUZYX2d4ZVlTbHlxTEdoTW1SY3pJUWd0MGJpcDFJZWIwdmdCbjY5U19rdFZsazdPbUIyVkZtVzhMNA?oc=5","date":"2026-03-13","type":"pipeline","source":"Stock Titan","summary":"Elutia grants 460,000 stock options to 3 new hires at $1.09 - Stock Titan","headline":"Elutia grants 460,000 stock options to 3 new hires at $1.09","sentiment":"neutral"},{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNSUtlUlFLbmpXa0Y4dllhazBjaE5DdmtYNGQweWNPMEZ4OGtXc1FzSGxqaUstWlN5WkJTX3lJZ3o2bFVnMXFNZmRzenM0SlZPNTZoaHJuLXY5Q0FuMFJsLXhKS0x4cURpUlFSdHdYdnZ1Smg2RHlJUmllNTJFblEyckV4aGtuMHFXOE9FOVJNU2RLVlNoWWg5cFhBSkczWUEyRFNHSUtHWHJmbUpnOTJBYWdEeDBJOS1rV1NRYUl1UQ?oc=5","date":"2026-03-02","type":"pipeline","source":"Stock Titan","summary":"New Elutia CCO targets 15–20% infection rates in breast reconstruction - Stock Titan","headline":"New Elutia CCO targets 15–20% infection rates in breast reconstruction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNWnVjUEFBRTdkZ1pxamVyRmc5MHBhOFU0RzJ5RXI0bnUwSjlQSnRZWFBtYzBsZ0tQMXJwejBhcTBULVlDbXpEdDBEUXpFWG1yVzRsRUFNU3lmaGZqVzNJQ1FIMTJqQjAzSnJDaWxWRGxuOThwMk1RVUU2a0pCMjZibVo5WjZxT3V6czlHMDJvbmh1eDRyTTZB?oc=5","date":"2026-02-23","type":"pipeline","source":"The Wall Street Transcript","summary":"Interview with the President and CEO: Elutia Inc. (NASDAQ:ELUT) - The Wall Street Transcript","headline":"Interview with the President and CEO: Elutia Inc. (NASDAQ:ELUT)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-15","type":"pipeline","source":"simplywall.st","summary":"Elutia Inc. (NASDAQ:ELUT) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st","headline":"Elutia Inc. (NASDAQ:ELUT) Surges 28% Yet Its Low P/S Is No Reason For Excitement","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNV0lvNjZpY3ZPVmdEM09VVUJWN0ZhcW1GZmlBei14SUtyNUdWQVBmT2FyTDhxT2dfNnNJb2ctRkJZZVpULUpQZ0o5cnIxWlVLbnhvQ3U0S3VYdERkb2V2SHZuOEVQUE53NWJrOG5QYjhxRVYxSHJJTkRqYm9la0l0MlVFeUZ0TGtxeVNpd2VqSjdpUmxzOFBCMnRvczZEbXEyNkphQmNVUnNobHFSanI1WlRnY0xXak5SLWZB?oc=5","date":"2025-10-01","type":"deal","source":"Stock Titan","summary":"$88M Deal: Elutia Sells BioEnvelope to Boston Scientific, Targets $1.5B Breast Reconstruction Market - Stock Titan","headline":"$88M Deal: Elutia Sells BioEnvelope to Boston Scientific, Targets $1.5B Breast Reconstruction Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOQlZaTTgzczRlQ3Z2aG9QemFxS3BHN2hVbnYwVXN4aGNQVEw3cmpnWURYMkNZNHRzdXdObEJsVU1SSElVa2ZZdFRLZzRHZmdTcjRKcUQ2UWF4czBTdFZtOFdzakYtakp6SnNUSHdINGc4ZXFVZ25WNnpTNktrdF9laVhPN25adm43cUtKWTJ4MXZVUUlrbkZUU2piMUdtd05sSFZWcmstbWdITUR4a3pR?oc=5","date":"2025-09-09","type":"pipeline","source":"The Business Journals","summary":"Gaithersburg’s Elutia selling key business line to Boston Scientific, sets sights on new products - The Business Journals","headline":"Gaithersburg’s Elutia selling key business line to Boston Scientific, sets sights on new products","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-19","type":"pipeline","source":"simplywall.st","summary":"US$6.50: That's What Analysts Think Elutia Inc. (NASDAQ:ELUT) Is Worth After Its Latest Results - simplywall.st","headline":"US$6.50: That's What Analysts Think Elutia Inc. (NASDAQ:ELUT) Is Worth After Its Latest Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNWTFuZWZCZHVFRENnOGlEOTJOdGFXRTlGYkhja05ablZWdWoxbFJIQWdFaWJyVEVVcmo5R1BSTE93Z1BBci01TDdLRWd0UVpjZ3lSb3lMOTlNU1NaSWthVzY1T0pHUk4ySm5POFNDYXZkdHdtcHBqcnhIazZXZTVBSEZ1YldoYVFTYTNNMlFDM083d1Zpenp1TktRZnJlcjJmXzhqLWdQT0RndnhMTUVFMkdrQ056b3BTRVNyTnNfRXgxeTUyX0JYbDIySWs3eTE4Qy1aWnkxZENrUVE1R25sSXpLWVBBQnJoQ2JWaDlKTjdkTnRNMl9v?oc=5","date":"2024-09-05","type":"regulatory","source":"BioSpace","summary":"Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators - BioSpace","headline":"Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and","sentiment":"neutral"}],"patents":[{"drugName":"Tissue Repair Technology","drugSlug":"tissue-repair-technology","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Stryker","Medtronic","Johnson & Johnson"],"therapeuticFocus":["Wound Care","Orthopedic Repair"],"financials":{"source":"sec_edgar+yahoo","revenue":12293000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":12293000},{"period":"2024-12-31","value":14467000},{"period":"2023-12-31","value":24745000},{"period":"2022-12-31","value":23849000}],"grossProfit":6596000,"grossProfitHistory":[{"period":"2025-12-31","value":6596000},{"period":"2024-12-31","value":6715000},{"period":"2023-12-31","value":11053000},{"period":"2022-12-31","value":11639000}],"rdSpend":4163000,"rdSpendHistory":[{"period":"2025-12-31","value":4163000},{"period":"2024-12-31","value":2998000},{"period":"2023-12-31","value":4399000},{"period":"2022-12-31","value":7727000}],"sgaSpend":20845000,"operatingIncome":-18412000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-18412000},{"period":"2024-12-31","value":-19344000},{"period":"2023-12-31","value":-20537000},{"period":"2022-12-31","value":-29989000}],"netIncome":53380000,"netIncomeHistory":[{"period":"2025-12-31","value":53380000},{"period":"2024-12-31","value":-53949000},{"period":"2023-12-31","value":-37656000},{"period":"2022-12-31","value":-32897000}],"eps":-1.86,"epsHistory":[{"period":"2024-12-31","value":-1.86},{"period":"2023-12-31","value":-2.07},{"period":"2022-12-31","value":-2.38},{"period":"2021-12-31","value":-2.38}],"cash":36350000,"cashHistory":[{"period":"2025-12-31","value":36350000},{"period":"2024-12-31","value":13239000},{"period":"2023-12-31","value":19276000},{"period":"2022-12-31","value":16989000}],"totalAssets":62350000,"totalLiabilities":34678000,"totalDebt":3942000,"equity":27672000,"operatingCashflow":-44810000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-44810000},{"period":"2024-12-31","value":-22657000},{"period":"2023-12-31","value":-21761000},{"period":"2022-12-31","value":-21434000}],"capex":-1876000,"capexHistory":[{"period":"2025-12-31","value":-1876000},{"period":"2024-12-31","value":-654000},{"period":"2023-12-31","value":-346000},{"period":"2022-12-31","value":-540000}],"freeCashflow":-46686000,"dividendsPaid":null,"buybacks":null,"employees":25,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":6190000,"ebit":-5491000,"ebitda":-5194000,"period":"2025-12-31","revenue":3271000,"epsBasic":1.66,"netIncome":70791000,"rdExpense":1215000,"epsDiluted":1.48,"grossProfit":1914000,"operatingIncome":-5491000},{"sga":5120000,"ebit":-110000,"ebitda":618000,"period":"2025-09-30","revenue":3323000,"epsBasic":-0.09,"netIncome":-3868000,"rdExpense":1088000,"epsDiluted":-0.19,"grossProfit":1853000,"operatingIncome":-4355000},{"sga":7473000,"ebit":-9084000,"ebitda":-8192000,"period":"2025-06-30","revenue":6263000,"epsBasic":-0.23,"netIncome":-9610000,"rdExpense":1456000,"epsDiluted":-0.26,"grossProfit":3058000,"operatingIncome":-5871000},{"sga":6902000,"ebit":-2840000,"ebitda":-1972000,"period":"2025-03-31","revenue":6030000,"epsBasic":-0.1,"netIncome":-3933000,"rdExpense":905000,"epsDiluted":-0.21,"grossProfit":2457000,"operatingIncome":-5350000},{"sga":7311000,"ebit":-7989000,"ebitda":-7126000,"period":"2024-12-31","revenue":5468000,"epsBasic":-0.26,"netIncome":-9061000,"rdExpense":834000,"epsDiluted":-0.26,"grossProfit":2324000,"operatingIncome":-5821000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.03,"previousClose":1.05,"fiftyTwoWeekHigh":2.64,"fiftyTwoWeekLow":0.5,"fiftyTwoWeekRange":"0.5 - 2.64","fiftyDayAverage":1.09,"twoHundredDayAverage":1.1,"beta":0.76,"enterpriseValue":12516090,"forwardPE":-0.9,"priceToBook":1.6,"priceToSales":3.92,"enterpriseToRevenue":1.02,"enterpriseToEbitda":-0.73,"pegRatio":0,"ebitda":-17196000,"ebitdaMargin":-139.9,"freeCashflow":-25104500,"operatingCashflow":-44810000,"totalDebt":3942000,"debtToEquity":14.2,"currentRatio":2.22,"returnOnAssets":-23.4,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":5,"targetHighPrice":5,"targetLowPrice":5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.6,"institutionHeldPercent":49.6,"sharesOutstanding":44208236,"floatShares":24892225,"sharesShort":126205,"shortRatio":1.81,"shortPercentOfFloat":0.3,"epsTrailing":-0.64,"epsForward":-1.1,"revenuePerShare":0.3,"bookValue":0.65,"officers":[{"age":53,"name":"Dr. C. Randal Mills Ph.D.","title":"Co-Founder, President, CEO & Director"},{"age":57,"name":"Mr. Matthew B. Ferguson","title":"Chief Financial Officer"},{"age":50,"name":"Dr. Michelle LeRoux Williams Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Ms. Tamara  Grossett","title":"Head of People"},{"age":null,"name":"Dr. Sonali  Fonseca Ph.D.","title":"VP & Head of Emerging Businesses"},{"age":57,"name":"Mr. Dwayne  Montgomery","title":"Head of Cardiovascular"},{"age":null,"name":"Mr. Peter J. Ligotti","title":"Chief Commercial Officer"},{"age":null,"name":"Mr. Jeffry D. Hamet","title":"Senior VP of Finance, Treasurer & Secretary"}],"industry":"Medical Devices","irWebsite":"","website":"https://elutia.com","phone":"240 247 1170"}}